Scancell Holdings (SCLP)
SCLP Share PerformanceMore
|52 week high||16.950 24/08/17|
|52 week low||9.675 11/05/17|
|52 week change||-1.000 (-6.90%)|
|4 week volume||7,348,162 22/01/18|
Media for (SCLP)
Latest News« previous» nextMore
16/02/2018 - 11:30 RNS
RNS Number: 0690F Scancell Holdings Plc 16 February 2018 16 February 2018 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to present at the Calculus Investor Forum Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Cliff Holloway, Chief Executive Officer and Lind...
15/02/2018 - 08:19 StockMarketWire
Scancell, a developer of novel immunotherapies for the treatment of cancer, has signed a worldwide licensing and collabor...
15/02/2018 - 07:15 RNS
RNS Number: 9320E Scancell Holdings Plc 15 February 2018 Hardman Research - Validating multiple opportunities Validating and de-risking of multiple opportunities: Scancell is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody is a DNA vaccine that stimulates high...
15/02/2018 - 07:00 RNS
RNS Number: 9322E Scancell Holdings Plc 15 February 2018 ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufactur ing , development and commerciali s ation of Modi-1 / AMPLIVANT combination AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019 Collaboration seeks to further leverage Moditope platform Leiden, The ...
12/02/2018 - 09:45 StockMarketWire
Scancell Holdings said it continued to collect positive results from patient trials for a cancer treatment. Overall, 18 of 20 stag...
12/02/2018 - 07:00 RNS
RNS Number: 5035E Scancell Holdings Plc 12 February 2018 12 February 2018 Scancell Holdings Plc ("Scancell" or the "Company") Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients Compelling 5-year survival data with most resected stage III and IV patients remaining alive Phase 2 trial anticipated to start in H2 2018 Scancell Hold...
11/02/2018 - 23:40 Trends and Targets
FTSE THIS WEEK (FTSE:UKX) We should find a way of building our articles which gives folks an idea of which bit to r...
09/02/2018 - 14:28 StockMarketWire
Scancell Holdings said the European Patent Office had announced an intention to grant Scancell's patent application for its...
|Dividend yield||0 %|
Latest discussion posts More
“" FTSE THIS WEEK (FTSE:UKX) We should find a way of building our articles which gives folks an idea of which bit to read. Due to our habit of giving "if x then y" and "if a ...”▼
“https://twitter.com/Inga661/status/962621205516779520 From the daily mail”▼
Codes & Symbols
|Symbols||SCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment